Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Neuroone Medical Technologies (NMTC) over the last 11 years, with Q4 2025 value amounting to $3.6 million.

  • Neuroone Medical Technologies' Cash & Equivalents rose 21736.24% to $3.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 million, marking a year-over-year increase of 21736.24%. This contributed to the annual value of $6.6 million for FY2025, which is 35001.32% up from last year.
  • Neuroone Medical Technologies' Cash & Equivalents amounted to $3.6 million in Q4 2025, which was up 21736.24% from $6.6 million recorded in Q3 2025.
  • In the past 5 years, Neuroone Medical Technologies' Cash & Equivalents registered a high of $16.2 million during Q4 2021, and its lowest value of $1.1 million during Q4 2024.
  • Over the past 5 years, Neuroone Medical Technologies' median Cash & Equivalents value was $5.0 million (recorded in 2022), while the average stood at $6.0 million.
  • Per our database at Business Quant, Neuroone Medical Technologies' Cash & Equivalents plummeted by 7256.85% in 2024 and then surged by 39628.38% in 2025.
  • Quarter analysis of 5 years shows Neuroone Medical Technologies' Cash & Equivalents stood at $16.2 million in 2021, then plummeted by 71.16% to $4.7 million in 2022, then plummeted by 42.56% to $2.7 million in 2023, then tumbled by 57.69% to $1.1 million in 2024, then soared by 217.36% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q4 2025, $6.6 million for Q3 2025, and $8.0 million during Q2 2025.